A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects with Mild-to-Moderate Alzheimer's Disease.
Latest Information Update: 09 Feb 2017
Price :
$35 *
At a glance
- Drugs ABT 384 (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
- 19 Jul 2012 This study was terminated for futility according to the conference abstract
- 09 Aug 2011 Actual end date (Jul 2011) added reported by ClinicalTrials.gov